NCT05579353Recruiting
The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer
The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression
Source: ClinicalTrials.gov · Last updated 13 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 9 Oct 2022
- Start date
- 1 Jan 2023
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Jingbo Chen
- Diseases
- Colorectal cancer
- NCT number
- NCT05579353
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2023 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
- Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
Other
- Those who refuse to collect samples.
- Combining with distant multiple metastases of tumor
Who the study is looking for
- 1.18-80 years old.
- 2.18.5 \< BMI \< 27.9.
- 3\. The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Shandong First Medical University Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.